## 4 Conclusions  
Psoriasis is a multifaceted inflammatory skin condition influenced by various genetic factors. Understanding these genetic components is crucial for developing targeted and personalized treatments that may improve the patients' quality of life. This review has categorized the genes involved in psoriasis based on their impact on immunological mediators and pathways.  
Interleukins (ILs), human leukocyte antigens (HLAs), nuclear factor kappa B (NF-\(\kappa\)B) pathway genes, interferons (IFNs), and Janus kinase (JAK)-signal transducer and activator  
\begin{table}
\begin{tabular}{l l} \hline \hline
**Target Gene** & **Indirect Treatments** \\ \hline ERAP1 & Anti-IL12/23 \\ \hline HLA-C & Anti-TNF-\(\alpha\) \\ \hline SMG6, IMMT, UPK1A & Methotrexate \\ \hline IL1-\(\beta\) & Adalimumab \\ \hline STAT & Tofacitinib \\ \hline TNFAIP3 & Anti-TNF-\(\alpha\) \\ \hline \hline \end{tabular}
\end{table}
Table 3: The genes and their associated indirect treatments.  
of transcription (STAT) pathway genes were all implicated in psoriasis susceptibility and pathogenesis. Individuals with psoriasis may be genetically susceptible due to the immune dysregulation that occurs in the setting of specific, high-risk alleles. By targeting these genes and their related products, novel treatment strategies can be developed to directly inhibit the disease progression.  
Existing therapies, such as biologics that target specific ILs or receptors, have shown promise in managing psoriasis. However, further research is needed to optimize use, determine long-term safety profiles, and minimize potential adverse effects. Indirectly targeting factors associated with gene products, such as modulating the NF-kB pathway activity or inhibiting JAK-STAT signaling, also hold potential for future therapeutic interventions.  
The advancements in precision medicine and genomics have opened new avenues for personalized treatment approaches. By identifying specific gene targets, healthcare providers can tailor therapies to individual patients, leading to improved treatment outcomes and a higher quality of life. Additionally, exploring the shared mechanisms between psoriasis and other inflammatory diseases may uncover novel treatment strategies that can benefit a broader range of patients.  
In summary, this review highlights the importance of genetic factors in psoriasis and their potential as treatment targets. Continued research and collaboration in this field will be instrumental in transforming the lives of psoriasis patients and advancing our understanding of inflammatory skin conditions.  
Conceptualization, S.R.F.; methodology, H.A.P., R.R.R. and S.T.P.; investigation, H.A.P., R.R.R. and S.T.P.; writing--original draft preparation, H.A.P., S.T.P. and S.G.; writing--review and editing, H.A.P. and R.R.R.; visualization, H.A.P. and R.R.R.; supervision, S.R.F.; project administration, H.A.P. All authors have read and agreed to the published version of the manuscript.  
This research received no external funding.  
Not applicable.  
No new data were created or analyzed in this study. Data sharing is not applicable to this article.  
[PERSON], [PERSON], [PERSON], and [PERSON] have no conflict of interest to disclose. [PERSON] has received research, speaking, and/or consulting support from Eli Lilly and Company, GlaxoSmithKline/Stiefel, AbbVie, Janssen, Alovtech, vTv Therapeutics, Bristol-Myers Squibb, Samsung, Pfizer, Boehringer Ingelheim, Amgen, Dermavant, Arcutis, Novartis, Novan, UCB, Helsinn, Sun Pharma, Almirall, Galderma, Leo Pharma, Mylan, Celgene, Ortho Dermatology, Menlo, Merck and Co, Qurient, Forte, Arena, Biocon, Accordant, Argenx, Sanofi, Regeneron, the National Biological Corporation, Caremark, Teladoc, BMS, Ono, Microes, Eurofins, Informa, UpToDate, and the National Soriasis Foundation. He is the founder and part owner of Causa Research and holds stock in Sensal Health.